Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

190.44
-1.2500-0.65%
Volume:272.77K
Turnover:52.33M
Market Cap:3.75B
PE:83.89
High:197.00
Open:194.61
Low:189.17
Close:191.69
52wk High:212.49
52wk Low:93.58
Shares:19.68M
Float Shares:19.16M
Volume Ratio:1.63
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.27
EPS(LYR):-0.2204
ROE:5.42%
ROA:1.48%
PB:3.94
PE(LYR):-863.88

Loading ...

MedCap AB erzielt im Gesamtjahr 2025 einen Umsatz von 2.108 Mio. SEK und eine EBITA-Marge von 18 Prozent

Reuters
·
Feb 06

Ligand Pharmaceuticals Director John W. Kozarich Reports Disposal of Common Shares

Reuters
·
Feb 05

Ligand Pharmaceuticals (LGND) Valuation Check As Partner Milestones Expand Royalty And Growth Potential

Simply Wall St.
·
Feb 05

Ligand Pharmaceuticals Executives to Participate in Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Feb 04

Agilent Technologies kooperiert mit Virscidian zur Integration von OpenLab CDS und Analytical Studio

Reuters
·
Feb 03

Atlas Copco übernimmt deutschen Filterspezialisten Zind Verfahrenstechnik

Reuters
·
Feb 03

Ligand Pharmaceuticals (LGND) Is Up 7.6% After Raising Long-Term Royalty Growth Outlook - What's Changed

Simply Wall St.
·
Jan 13

Ligand Pharmaceuticals Director John W. Kozarich Reports Sale of Common Shares

Reuters
·
Jan 07

Ligand Pharmaceuticals CFO Octavio Espinoza Reports Sale of Common Shares

Reuters
·
Dec 17, 2025

Raised 2026 Royalty Outlook and $1 Billion Plan Could Be A Game Changer For Ligand (LGND)

Simply Wall St.
·
Dec 11, 2025

Ligand Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
Dec 10, 2025

Citigroup Initiates Ligand Pharmaceuticals at Buy With $270 Price Target

MT Newswires Live
·
Dec 09, 2025

Ligand Pharmaceuticals Reiterates 2025 Outlook, Issues 2026 Guidance

MT Newswires Live
·
Dec 09, 2025

GUIDANCE: (LGND) Ligand Pharmaceuticals Expects Full Year 2026 Core Adjusted EPS Range $8 to $9, vs. FactSet Est of $7.97

MT Newswires Live
·
Dec 09, 2025

Ligand Pharmaceuticals Inc - $1 Bln Deployable Capital to Drive Royalty Revenue Growth

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Inc - Introduces 2026 Revenue Guidance of $245-$285 Mln

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Inc: Reiterate Its 2025 Guidance

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Inc - 2026 Core Adj EPS Expected at $8.00-$9.00

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $270

THOMSON REUTERS
·
Dec 09, 2025

Ligand Pharmaceuticals Director John W. Kozarich Reports Sale of Common Shares

Reuters
·
Dec 04, 2025